Skip to main content
OpenTrials
Completed

NCT Number: NCT00156156

Study of Asoprisnil in the Treatment of Uterine Fibroids.

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Fibroid Uterus Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Hemorrhage Leiomyoma Menorrhagia Menstruation Disturbances Metrorrhagia Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Pathologic Processes Pathological Conditions, Signs and Symptoms Urogenital Diseases Uterine Diseases Uterine Fibroids Uterine Hemorrhage

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

About this study

No medical therapy is currently available for the long-term treatment of abnormal uterine bleeding associated with uterine fibroids in women and many women must resort to surgery for relief. The objective of this study is to determine the long-term safety of two asoprisnil doses (10 and 25 mg tablets) administered daily to women who received asoprisnil in one of the asoprisnil long-term studies (study C03-062 or study M01-391). The safety endpoints for this study will include the affects of asoprisnil on the endometrium, ovaries, bone (a subset of study M01-391 subjects), lipid profiles, adverse events, and changes from baseline lab values and vital signs.

Some subjects receiving asoprisnil developed endometrial changes. As a result, dosing was prematurely discontinued for all subjects. To ensure safety, subjects will remain on study and will undergo scheduled study procedures. In most subjects, endometrial changes reversed after asoprisnil discontinuation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women who have completed 12 months of active treatment in study M01-391 and Month 12 visit procedures Or completed 18 months of active treatment in study C03-062 and Month 18 visit procedures (with no more than a 14-day interruption in dosing from study C02-062 and this study) OR could not continue in a previous asoprisnil study, but are now eligible for retreatment
  • Otherwise in good health
  • Premenopausal based on Estrogen and FSH levels
  • Adequate endometrial biopsy with no significant histological disorder
  • Agrees to use double-barrier method of contraception

Exclusion criteria

  • Any abnormal lab or procedure result(s) the study-doctor considers important
  • History of a blood-clotting disorder
  • History of osteoporosis requiring treatment
  • Any invasive procedure(s) (D&C, etc) where a polyp was confirmed or a surgical or invasive procedure for uterine fibroids was performed during any previous asoprisnil study
  • Hemoglobin < 8.0 g/dL
  • Endometrial thickness ≥ 19 mm

Treatment and study plan

Asoprisnil

Drug

Asoprisnil 10 mg Tablet, oral Daily for up to 2 years

Other names: J867

Primary outcomes

  1. Long-term Safety.

    Time frame: Throughout 2 year treatment period

Secondary outcomes

  1. Change from baseline in the monthly bleeding score and the number of days with bleeding.

    Time frame: Each Month

  2. Change from baseline in hemoglobin, hematocrit, TIBC, ferritin and iron concentrations.

    Time frame: Months 3, 6, 9,12,15,18, 24

  3. Percent change from baseline in volume of the largest fibroid.

    Time frame: Months 12, 24

  4. Change from baseline in bloating, pelvic pressure, dysmenorrhea and urinary symptoms.

    Time frame: Months 6, 12, 18, 24

  5. Change from baseline in total symptom severity score and the Uterine Fibroid Symptoms-Quality of Life total score.

    Time frame: Months 6, 12, 18, 24

  6. Change from baseline in the 8 scales of the SF-36 questionnaire.

    Time frame: Months 6, 12, 18, 24

  7. Change from baseline in the 4 scales and overall index of the Work Limitations Questionnaire.

    Time frame: Months 6, 12, 18, 24

  8. Cumulative percent of subjects who achieve amenorrhea.

    Time frame: Each Month

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

A Phase 3, Continuation Study to Evaluate the Long-Term Safety of Asoprisnil in Subjects With Uterine Leiomyomata

Important dates

Study start
2004
Primary completion
2007
Study completion
2007
First posted
Sep 12, 2005
Registry last updated
May 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.